Navigation Links
Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
Date:5/3/2011

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that several members of management will speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing.  The conference is taking place May 8-11, 2011 at the Toronto Convention Center.  

  • James Levine, President and Chief Executive Officer, will make opening remarks at a plenary breakfast, What Consumers and Manufacturers Need from Industrial Biotech Companies: A Customer Perspective on Tuesday, May 10th at 7:00 am.
  • Janet Roemer, Chief Operating Officer, will be moderating a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, on Wednesday, May 11th at 11:00 am. Roemer will also be speaking on a panel, The Power of Enzymes, Tuesday, May 10th at 3:00 pm
  • Ken Barrett, Vice President, Business Development, will be moderating a panel, Protein Engineering and Screening Methods, Tuesday, May 10th at 9:00 am.
  • David Weiner, Ph.D., Vice President, R&D Strategy and Partnerships, will be speaking on a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, Wednesday, May 11th at 11:00 am.

  • The Company will also have a booth at space 316 in the Toronto Convention Center.

    For more information on the BIO Industrial Biotechnology Conference please visit http://www.bio.org/worldcongress/index.asp

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel marke
    '/>"/>

    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, ... using the genome to create better medicine, today congratulated the ... studies of whole-genome data yet undertaken. The ... – are built around the most comprehensive population-wide ... of deCODE scientists led by Kari Stefansson , deCODE,s ...
    (Date:3/25/2015)... 2015 Having added two International locations ... of 2014, ITRA Global proudly announced recently the organization’s ... Representative Alliance, based in the United States, is one ... occupiers of commercial real estate. , Saltwood International ... Poland that exclusively advises occupiers of office space, ensuring ...
    (Date:3/25/2015)... TORONTO , March 25, 2015 /CNW/ - ... winners of the 2015 Canada Gairdner Awards, recognizing some ... the world. Among the world,s ... a leader in science and provide a $100,000 (CDN) prize ... promote a stronger culture of research and innovation ...
    (Date:3/25/2015)... 25, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announces ... its target therapy drug candidate ENMD-2076 in triple-negative breast ... of Medical Sciences in Beijing , ...
    Breaking Biology Technology:Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2International Organization Expands its Global Reach to Warsaw, Poland 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 22015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 32015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 42015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 52015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 62015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 72015 Canada Gairdner Awards Honour Top Medical Discoveries Around The World 8CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 4CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 5
    ... Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/,-- Curis, ... development company focused on,developing proprietary targeted medicines for ... companies with a focus on the development of,prescription ... that they,have entered into a worldwide, exclusive license ...
    ... China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced the appointment of Mr.,William Wei Lee as an ... effective August 4, 2009. Mr. Jiang Qi-Feng resigned from ...
    ... 6 Interleukin Genetics, Inc. (NYSE Amex: ... conference call and webcast on Thursday, August 13, 2009, at 4:30 ... financial results. , , To access the live ... replay access of the teleconference will be available on the Investors ...
    Cached Biology Technology:Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 2Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 3Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 4Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 5Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 6China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3
    (Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
    (Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
    (Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
    Breaking Biology News(10 mins):Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
    ... WASHINGTON, Oct. 18 Can skin cancer be treated ... Irvine), believe so. They,re exploring new ways to image cancerous ... cancer called photodynamic therapy (PDT) -- work that they will ... in Optics (FiO) 2010 at the Rochester Riverside Convention ...
    ... Health (NIH) have determined the complete genetic blueprints for ... bacteria that cause Lyme disease. The achievement should lead ... strains may result in different courses of illness in ... in North America. The wealth of new genetic data ...
    ... University of Michigan Heath System and their collaborators have ... help guide new treatments for psoriasis, one of the ... Using cutting-edge methods to peer into the hidden genetic ... published in Nature Genetics, further maps the ...
    Cached Biology News:Treating cancer with light 2Four new psoriasis 'hotspots' identified by U-M geneticists 2
    Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
    ... (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. A ... Has reduced electrostatic interactions that do not ... Aggregation number: 8-16. Purity: ≥95% by ... Aggregation number 8 - 16, CMC 1.1 ...
    ... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
    ... Goat polyclonal to PAX3 This protein ... (PAX) family of transcription factors. Members of ... box domain and a paired-type homeodomain. These ... Mutations in paired box gene 3 are ...
    Biology Products: